A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms
This study is testing a new combination of a targeted therapy drug called venetoclax alongside standard chemotherapy to treat aggressive forms of leukemia. The goal is to see if adding venetoclax makes the treatment more effective at killing cancer cells while keeping patients safe.
This trial is for adults 18 or older who have been diagnosed with acute myeloid leukemia or other high-grade blood cancers that are either newly diagnosed as high-risk, have returned after treatment, or did not respond to previous therapy.
Participants will receive a combination of chemotherapy drugs and venetoclax. Throughout the study, you will have regular check-ups, blood tests, and bone marrow samples taken to monitor how your body is responding to the treatment.
This study is currently recruiting patients and is taking place in Seattle, Washington.
- 1Researchers are testing if adding a targeted drug to chemotherapy can better fight aggressive leukemia.
- 2The study is designed for adults with high-risk or treatment-resistant blood cancers.
- 3Participants will receive close medical monitoring and regular diagnostic tests throughout the trial.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.